AKTS · Nasdaq · CIK 0002035832

Aktis Oncology, Inc.

Aktis Oncology, Inc.’s most recent SEC filing in our snapshot is a Form 4 filed on Sep 24, 2026. Its EDGAR record lists 13 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue
—
Net income
—
Form 4 filings on record, past 12 months
13

Company overview

Legal name (as filed)
Aktis Oncology, Inc.
Ticker
AKTS
SEC Central Index Key (CIK)
0002035832
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
BOSTON, MA
State or country of incorporation
DE
Fiscal year ends
December 31
SEC filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Position in SEC ticker list
#2479 of the 3,000 companies we track

Five-year financial highlights

We could not find standardized annual figures for Aktis Oncology, Inc. in the SEC’s XBRL company facts. Read the latest annual report directly on EDGAR.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

AKTS latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Mar 30, 202610-KAnnual report· period Dec 31, 2025Document · Index
Aug 13, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 13, 20268-KResults of operations· period Aug 13, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Aktis Oncology, Inc., by form type:

4 ×133 ×5144 ×58-K ×5SCHEDULE 13D ×410-Q ×2SCHEDULE 13G ×110-K ×1S-8 ×1424B4 ×1EFFECT ×1CERT ×1
AKTS recent filings
FiledFormWhat it isOriginal
Sep 24, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 23, 2026Document · Index
Sep 23, 2026144Notice of proposed sale of securitiesDocument · Index
Aug 13, 202610-QQuarterly report· period Jun 30, 2026Document · Index
Aug 13, 20268-KResults of operations· period Aug 13, 2026Document · Index
Jul 21, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 20, 2026Document · Index
Jul 20, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 20, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 17, 2026Document · Index
Jul 17, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 10, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 8, 2026Document · Index
Jul 10, 20264Statement of changes in beneficial ownership (insider trade)· period Jul 8, 2026Document · Index
Jul 8, 2026144Notice of proposed sale of securitiesDocument · Index
Jul 8, 2026144Notice of proposed sale of securitiesDocument · Index
May 14, 2026SCHEDULE 13GPassive beneficial ownership report (over 5%)Document · Index
May 11, 202610-QQuarterly report· period Mar 31, 2026Document · Index
May 11, 20268-KResults of operations· period May 11, 2026Document · Index
Apr 16, 20264Statement of changes in beneficial ownership (insider trade)· period Apr 15, 2026Document · Index
Apr 16, 20263Initial statement of beneficial ownership· period Apr 15, 2026Document · Index
Apr 16, 20268-KDirector or officer change; Regulation FD disclosure· period Apr 15, 2026Document · Index
Mar 30, 20268-KResults of operations· period Mar 30, 2026Document · Index
Mar 30, 202610-KAnnual report· period Dec 31, 2025Document · Index
Jan 20, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Jan 20, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Jan 15, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Jan 15, 20263Initial statement of beneficial ownership· period Jan 12, 2026Document · Index
Jan 14, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 12, 2026Document · Index
Jan 14, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 12, 2026Document · Index
Jan 14, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 12, 2026Document · Index
Jan 14, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Jan 12, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 12, 2026Document · Index
Jan 12, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 12, 2026Document · Index
Jan 12, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 12, 2026Document · Index
Jan 12, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Jan 12, 20268-KCharter, bylaws or fiscal year change· period Jan 12, 2026Document · Index
Jan 12, 20264Statement of changes in beneficial ownership (insider trade)· period Jan 12, 2026Document · Index
Jan 9, 2026424B4424B4Document · Index
Jan 8, 2026EFFECTEFFECTDocument · Index
Jan 8, 20263Initial statement of beneficial ownership· period Jan 8, 2026Document · Index
Jan 8, 2026CERTCERTDocument · Index
Jan 8, 20263Initial statement of beneficial ownership· period Jan 8, 2026Document · Index
Jan 8, 20263Initial statement of beneficial ownership· period Jan 8, 2026Document · Index

Insider filing activity

13 Form 4 filings appear in Aktis Oncology, Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations· Companies headquartered in Massachusetts

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0002035832 and XBRL company facts. Aktis Oncology, Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.